K-pop hitmaker Shinsadong Tiger dies at 41
Hospitals experience disruptions on extended doctors' walkout
Parents of 7 first to receive W10m for childbirth in Seoul
G7 leaders decry N. Korea's exports of ballistic missiles to Russia
Occult thriller 'Exhuma' reaches 1m ticket sales in record time
Tours of royal hall at Changdeokgung to open
[Weekender] Discover the joys of life without a smartphone
Two students of Priest Lee Tae-seok become medical specialists
Enjoy Danyang with unique cafes and dynamic activities
SK bioscience's typhoid conjugate vaccine wins WHO prequalification certification
Celltrion revs up for Xolair biosimilar’s phase 3 clinical trialBy Lim Jeong-yeo
Published : Oct. 8, 2020 - 14:06
The company plans to begin the late stage human test of the pipeline first in Korea, and expand to 600 patients suffering from chronic spontaneous urticaria in seven countries.
So far, in Australia, Celltrion has gained midterm data for the drug’s safety in the human body from the phase 1 clinical trial that is being carried out there.
The global clinical phase 3 trial will be finalized in 2023, Celltrion said.
CT-P39 is a protein replicate of the blockbuster allergy treatment Xolair (omalizumab) that aims to become a more affordable alternative for allergic asthma and chronic spontaneous urticaria.
Xolair, marketed by Genentech and Novartis, is a drug highly in demand that raked in global annual revenue of 3.9 trillion won ($3.37 billion) in 2019.
Unlike novel drug development that starts from a base of zero, CT-P39 as a biosimilar has only to prove its similarity to Xolair in order to receive approval for market distribution.
By Lim Jeong-yeo (firstname.lastname@example.org)
Medical grads abandon internships, robbing hospitals of respite hopes
Death & denial: Why Koreans refuse to contemplate the end
Anti-Yoon vs anti-establishment: Main parties’ election strategies take shape